Ingolf Cascorbi

Professor, Director

Kiel University

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

ORCID

Google Scholar

Academic Page

About

Ingolf Cascorbi is a Professor and Director at Kiel University in Germany. His research areas include pharmacogenomics, the modulation of drug responses in chronic myeloid leukemia, and the molecular mechanisms of neuroblastoma. Recent articles by Dr. Cascorbi focus on biosimilars, the impact of comorbidities in heart diseases, and the educational needs in pharmacogenomics. He actively explores the interplay between genetic factors and drug metabolism in various therapeutic contexts.

Ingolf Cascorbi

Research Interests

Explore related searches

Contact this professor

About

Articles (22)

Interchanging Biosimilars Using Proteomics

Deciphering the Relative Contribution of CYP3A4 Versus P‐Glycoprotein for the Shared Substrate Cyclosporine—Commentary on Lown et al.

Regulation and Function of CCL2 and N-Myc in Retinoic Acid-treated Neuroblastoma Cells

Phenotype–Genotype Correlation Applying a Cocktail Approach and an Exome Chip Analysis Reveals Further Variants Contributing to Variation of Drug Metabolism

Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol

Komorbiditäten bei Herzerkrankungen – Ausmaß und Folgen

Tuning of liver circadian transcriptome rhythms by thyroid hormone state in male mice

Analysis of the current situation of pharmacogenomics in terms of educational and healthcare needs in Egypt and Lebanon

BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia

Encouraging medical students to become surgeons? Impact of psychological and surgical factors on career choice at medical school,Nachwuchsförderung für die operativen Fächer? Einfluss psychologischer und operativer Faktoren auf die berufliche Orientierung im Medizinstudium

Enhancing Retinoic Acid-mediated Effects Through Inhibition of CYP26A1, CYP26B1 and HGF Signaling in Neuroblastoma Cells

Liver microRNA transcriptome reveals miR-182 as link between type 2 diabetes and fatty liver disease in obesity

Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms

Why is There Still Debate About Recommending DPYD‐Testing Before Fluoropyrimidine Treatment?

Clinical Pharmacology of Cannabinoid Therapeutics: Drug Interactions and Side Effects

Polypharmazie – Interaktionen bei älteren Menschen

Pharmacovigilance‐based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections

ZFP36L1 plays an ambiguous role in the regulation of cell expansion and negatively regulates CDKN1A in chronic myeloid leukemia cells

Interaction of Phytocompounds of Echinacea purpurea with ABCB1 and ABCG2 Efflux Transporters

Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance

Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions

Alternative Polyadenylation of ABC Transporters of the C-Family (ABCC1, ABCC2, ABCC3) and Implications on Posttranscriptional Micro-RNA Regulation

Collaborators (4)

Jens Mittag

Stefan Oswald

Oliver Rawashdeh

Ann Daly

How do I reach out?

Meet Kite AI